Detalhe da pesquisa
1.
Efficacy of DYRK1A inhibitors in novel models of Down syndrome acute lymphoblastic leukemia.
Haematologica
; 2024 Feb 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-38426275
2.
Down syndrome and leukemia: from basic mechanisms to clinical advances.
Haematologica
; 108(10): 2570-2581, 2023 10 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37439336
3.
Human erythroleukemia genetics and transcriptomes identify master transcription factors as functional disease drivers.
Blood
; 136(6): 698-714, 2020 08 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-32350520
4.
It is more "unbalanced" than you think.
Blood
; 141(10): 1095-1096, 2023 03 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-36893009
5.
SNAIL trail in myeloid malignancies.
Blood
; 136(8): 920-921, 2020 08 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-32818247
6.
Ikaros inhibits megakaryopoiesis through functional interaction with GATA-1 and NOTCH signaling.
Blood
; 121(13): 2440-51, 2013 Mar 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-23335373
7.
Development of acute megakaryoblastic leukemia in Down syndrome is associated with sequential epigenetic changes.
Blood
; 122(14): e33-43, 2013 Oct 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-23980066
8.
Romidepsin enhances the efficacy of cytarabine in vivo, revealing histone deacetylase inhibition as a promising therapeutic strategy for KMT2A-rearranged infant acute lymphoblastic leukemia.
Haematologica
; 104(7): e300-e303, 2019 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-30679330
9.
The ETO2 transcriptional cofactor maintains acute leukemia by driving a MYB/EP300-dependent stemness program.
Hemasphere
; 8(6): e90, 2024 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-38903535
10.
Characterization of mesenchymal stem cells in pre-B acute lymphoblastic leukemia.
Front Cell Dev Biol
; 11: 1005494, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-36743421
11.
Preclinical efficacy of azacitidine and venetoclax for infant KMT2A-rearranged acute lymphoblastic leukemia reveals a new therapeutic strategy.
Leukemia
; 37(1): 61-71, 2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36380143
12.
A biobank of pediatric patient-derived-xenograft models in cancer precision medicine trial MAPPYACTS for relapsed and refractory tumors.
Commun Biol
; 6(1): 949, 2023 09 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-37723198
13.
Stepwise GATA1 and SMC3 mutations alter megakaryocyte differentiation in a Down syndrome leukemia model.
J Clin Invest
; 132(14)2022 07 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-35587378
14.
Insights into the manifestations, outcomes, and mechanisms of leukemogenesis in Down syndrome.
Blood
; 113(12): 2619-28, 2009 Mar 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-19139078
15.
Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies.
Blood
; 114(1): 144-7, 2009 Jul 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-19420352
16.
Preclinical Evaluation of Carfilzomib for Infant KMT2A-Rearranged Acute Lymphoblastic Leukemia.
Front Oncol
; 11: 631594, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-33937032
17.
DYRK1A regulates B cell acute lymphoblastic leukemia through phosphorylation of FOXO1 and STAT3.
J Clin Invest
; 131(1)2021 01 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33393494
18.
Building the Future Therapies for Down Syndrome: The Third International Conference of the T21 Research Society.
Mol Syndromol
; 12(4): 202-218, 2021 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-34421499
19.
Activating mutations in human acute megakaryoblastic leukemia.
Blood
; 112(10): 4220-6, 2008 Nov 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-18755984
20.
Gain of chromosome 21 in hematological malignancies: lessons from studying leukemia in children with Down syndrome.
Leukemia
; 34(8): 1984-1999, 2020 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-32433508